Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mesoblast Ltd Ads (MESO)

Mesoblast Ltd Ads (MESO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 435,071
  • Shares Outstanding, K 107,425
  • Annual Sales, $ 16,720 K
  • Annual Income, $ -89,800 K
  • 60-Month Beta 1.90
  • Price/Sales 26.08
  • Price/Cash Flow N/A
  • Price/Book 0.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.12 +29.80%
on 03/23/20
8.16 -50.37%
on 03/10/20
-3.95 (-49.37%)
since 02/27/20
3-Month
3.12 +29.80%
on 03/23/20
10.88 -62.78%
on 01/24/20
-3.35 (-45.27%)
since 12/27/19
52-Week
3.12 +29.80%
on 03/23/20
10.88 -62.78%
on 01/24/20
-0.95 (-19.00%)
since 03/27/19

Most Recent Stories

More News
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

GILD : 72.85 (-1.37%)
NVAX : 13.05 (+2.43%)
CANF : 1.3400 (-0.74%)
AIM : 2.04 (-0.49%)
MESO : 4.05 (-0.25%)
KALA : 7.38 (+0.54%)
Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L For Treatment Of COVID-19 Lung Disease

Mesoblast Limited (Nasdaq: MESO; ASX:MSB) today announced that it plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-L in patients with acute respiratory distress...

MESO : 4.05 (-0.25%)
Mesoblast Reports Financial Results and Corporate Highlights for First Half Ended December 31, 2019

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today reported financial, corporate and operational highlights for the half year ended December 31, 2019.

MESO : 4.05 (-0.25%)
Mesoblast to Host Analyst Call on First Half Financial Results for Period Ended December 31, 2019

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host an analyst call to discuss the financial results for the first half FY 2020 ended December...

MESO : 4.05 (-0.25%)
Consistent Outcomes Using Ryoncil(TM) as First-Line Treatment or Salvage Therapy in 309 Children With Steroid-Refractory Acute GVHD

Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that aggregated results from 309 children treated with Ryoncil(TM) (remestemcel-L) were presented at the American Society for Transplantation Cellular...

MESO : 4.05 (-0.25%)
Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the investigator-initiated expanded access protocol using its cryopreserved...

MESO : 4.05 (-0.25%)
Mesoblast Submits Completed Biologics License Application for Ryoncil(TM) to US FDA

Mesoblast Limited (Nasdaq: MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has submitted its completed Biologics License Application (BLA) to the...

MESO : 4.05 (-0.25%)
Will Mesoblast Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Mesoblast

MESO : 4.05 (-0.25%)
Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast

Zacks.com featured highlights include: China Distance Education, Intellicheck, Snap and Mesoblast

DL : 6.59 (-10.34%)
SNAP : 12.18 (+1.92%)
MESO : 4.05 (-0.25%)
IDN : 3.91 (-6.46%)
4 Affordable Breakout Stocks for Stunning Returns

Selecting breakout stocks continues to be one of the most popular methods among active investors.

DL : 6.59 (-10.34%)
SNAP : 12.18 (+1.92%)
MESO : 4.05 (-0.25%)
IDN : 3.91 (-6.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade MESO with:

Business Summary

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's...

See More

Key Turning Points

2nd Resistance Point 4.40
1st Resistance Point 4.23
Last Price 4.05
1st Support Level 3.86
2nd Support Level 3.66

See More

52-Week High 10.88
Fibonacci 61.8% 7.92
Fibonacci 50% 7.00
Fibonacci 38.2% 6.08
Last Price 4.05
52-Week Low 3.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar